Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

Canelo Alvarez is set to return to action on May 3 as he takes on William Scull for the undisputed light heavyweight title. After Scull, there has been talks of a potential showdown against ...

Boxing. Canelo Alvarez is one of Floyd Mayweather's favorite opponents for this shocking reason Boxing. Tyson Fury makes major announcement as fans call him out for falling into old habits Under ...

UFC. Oleksandr Usyk wants to fight Jake Paul... in MMA? Boxing. Oscar de la Hoya 'recognizes' Canelo Alvarez's greatness: "If you beat him, you go down in history" In a recent interview ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

After two defeats in finals, Edson Álvarez finally tasted silverware with the Mexico national team, captaining his side to CONCACAF Nations League success in the most recent international break. In ...

MEXICO CITY (AP) — Canelo Alvarez knows that fighting in the Middle East for the first time entails changes to his routine. Food will not be one of them, though. The Mexican boxer said on Friday ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

PHOENIX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today announced that it received a notice (“Notice”) on February 21, 2025 from ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp ...